Related Experiment Videos
[Clinical risk-adapted therapies in systemic sclerosis]
1Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie der Charité Universitätsmedizin, Centrum 12, Charité Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany. gabriela.riemekasten@charite.de
Zeitschrift Fur Rheumatologie
|November 13, 2007
Summary
Systemic sclerosis management requires risk assessment for tailored therapy. This paper explores risk-adapted strategies and novel treatments for high-risk patients with systemic sclerosis.
Area of Science:
- Rheumatology and Immunology
- Internal Medicine
Context:
- Systemic sclerosis presents significant challenges in early risk stratification and therapeutic decision-making.
- Clinical experience with over 450 patients informs this discussion.
Purpose:
- To propose a risk-adapted treatment strategy for systemic sclerosis.
- To highlight novel and future therapeutic options for refractory or high-risk patients.
Summary:
- This article reviews current literature and clinical experience to outline a risk-adapted approach to systemic sclerosis management.
- Emphasis is placed on advanced therapies for patients with poor prognosis or resistance to standard treatments.
- Potential future treatments include vasoactive, cellular, and immunosuppressive modalities.
Impact:
- Aims to guide clinicians in optimizing systemic sclerosis treatment based on individual patient risk.
- Provides insights into emerging therapies for severe or refractory cases of systemic sclerosis.
- Contributes to the ongoing development of evidence-based management protocols for systemic sclerosis.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...